Unravelling intrinsic efficacy and ligand bias at G protein coupled receptors: A practical guide to assessing functional data
- PMID: 26478533
- DOI: 10.1016/j.bcp.2015.10.011
Unravelling intrinsic efficacy and ligand bias at G protein coupled receptors: A practical guide to assessing functional data
Abstract
Stephenson's empirical definition of an agonist, as a ligand with binding affinity and intrinsic efficacy (the ability to activate the receptor once bound), underpins classical receptor pharmacology. Quantifying intrinsic efficacy using functional concentration response relationships has always presented an experimental challenge. The requirement for realistic determination of efficacy is emphasised by recent developments in our understanding of G protein coupled receptor (GPCR) agonists, with recognition that some ligands stabilise different active conformations of the receptor, leading to pathway-selective, or biased agonism. Biased ligands have potential as therapeutics with improved selectivity and clinical efficacy, but there are also pitfalls to the identification of pathway selective effects. Here we explore the basics of concentration response curve analysis, beginning with the need to distinguish ligand bias from other influences of the functional system under study. We consider the different approaches that have been used to quantify and compare biased ligands, many of which are based on the Black and Leff operational model of agonism. Some of the practical issues that accompany these analyses are highlighted, with opportunities to improve estimates in future, particularly in the separation of true agonist intrinsic efficacy from the contributions of system dependent coupling efficiency. Such methods are by their nature practical approaches, and all rely on Stephenson's separation of affinity and efficacy parameters, which are interdependent at the mechanistic level. Nevertheless, operational analysis methods can be justified by mechanistic models of GPCR activation, and if used wisely are key elements to biased ligand identification.
Keywords: Affinity; Agonist; Efficacy; G protein coupled receptor; Ligand bias; Operational model.
Copyright © 2015 Elsevier Inc. All rights reserved.
Similar articles
-
Biased agonism at G protein-coupled receptors: the promise and the challenges--a medicinal chemistry perspective.Med Res Rev. 2014 Nov;34(6):1286-330. doi: 10.1002/med.21318. Epub 2014 May 5. Med Res Rev. 2014. PMID: 24796277 Review.
-
What is biased efficacy? Defining the relationship between intrinsic efficacy and free energy coupling.Trends Pharmacol Sci. 2014 Dec;35(12):639-47. doi: 10.1016/j.tips.2014.09.010. Epub 2014 Oct 30. Trends Pharmacol Sci. 2014. PMID: 25448316
-
Fulfilling the Promise of "Biased" G Protein-Coupled Receptor Agonism.Mol Pharmacol. 2015 Sep;88(3):579-88. doi: 10.1124/mol.115.099630. Epub 2015 Jul 1. Mol Pharmacol. 2015. PMID: 26134495 Free PMC article. Review.
-
G Protein-coupled Receptor Biased Agonism.J Cardiovasc Pharmacol. 2016 Mar;67(3):193-202. doi: 10.1097/FJC.0000000000000356. J Cardiovasc Pharmacol. 2016. PMID: 26751266 Free PMC article. Review.
-
Refining efficacy: exploiting functional selectivity for drug discovery.Adv Pharmacol. 2011;62:79-107. doi: 10.1016/B978-0-12-385952-5.00009-9. Adv Pharmacol. 2011. PMID: 21907907 Review.
Cited by
-
Quantitative receptor model for responses that are left- or right-shifted versus occupancy (are more or less concentration sensitive): the SABRE approach.Front Pharmacol. 2023 Dec 15;14:1274065. doi: 10.3389/fphar.2023.1274065. eCollection 2023. Front Pharmacol. 2023. PMID: 38161688 Free PMC article.
-
Methodical Challenges and a Possible Resolution in the Assessment of Receptor Reserve for Adenosine, an Agonist with Short Half-Life.Molecules. 2017 May 19;22(5):839. doi: 10.3390/molecules22050839. Molecules. 2017. PMID: 28534854 Free PMC article.
-
Luciferase Complementation Approaches to Measure GPCR Signaling Kinetics and Bias.Methods Mol Biol. 2021;2268:249-274. doi: 10.1007/978-1-0716-1221-7_17. Methods Mol Biol. 2021. PMID: 34085274
-
The synthetic cannabinoid WIN55,212-2 mesylate decreases the production of inflammatory mediators in rheumatoid arthritis synovial fibroblasts by activating CB2, TRPV1, TRPA1 and yet unidentified receptor targets.J Inflamm (Lond). 2016 May 5;13:15. doi: 10.1186/s12950-016-0114-7. eCollection 2016. J Inflamm (Lond). 2016. PMID: 27158245 Free PMC article.
-
Novel and Potent Dopamine D2 Receptor Go-Protein Biased Agonists.ACS Pharmacol Transl Sci. 2019 Feb 8;2(1):52-65. doi: 10.1021/acsptsci.8b00060. Epub 2019 Jan 14. ACS Pharmacol Transl Sci. 2019. PMID: 30775693 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources